Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) is advancing its lead preclinical cancer candidate, ONC010, toward potential first-in-human testing by aligning drug manufacturing, nanoparticle formulation, analytical development, preclinical studies, and regulatory planning. The company’s integrated approach aims to streamline the path to clinical trials, a critical step in developing new cancer therapies.
ONC010 combines the company’s PNKP-targeting small molecule A83B4C63 with a micellar nanoparticle delivery system intended to enhance drug exposure and tumor accumulation. The broader strategy focuses on disrupting cancer cells’ DNA repair mechanisms, which could potentially enhance the effects of radiation and certain chemotherapy treatments. This mechanism is particularly significant because many cancers resist standard therapies by efficiently repairing DNA damage; inhibiting this repair could make treatments more effective.
Onco-Innovations has completed a 300-gram development batch of A83B4C63 at approximately 99.3% purity, a key milestone for ensuring consistent drug supply for preclinical and eventual clinical studies. The company has also advanced polymer manufacturing and identified a non-tin catalyst that could improve impurity control, addressing a common challenge in drug development. Additionally, pharmacokinetic, biodistribution, metabolism, and ADME studies are progressing, which are essential for understanding how the drug behaves in the body and informing safe dosing in humans.
With an Australian subsidiary established, clinical-development partners engaged, and new scientific and clinical leadership in place, Onco is working to integrate these activities into the manufacturing and regulatory package needed for a potential phase I/first-in-human study. This alignment is crucial for navigating the complex regulatory landscape and ensuring that all components are ready for clinical evaluation.
The potential impact of ONC010 extends beyond Onco-Innovations. If successful, it could offer a new way to enhance existing cancer treatments, particularly for solid tumors where DNA repair is a key resistance mechanism. The company has secured an exclusive worldwide license to patented technology that targets solid tumors, positioning it to address a significant unmet need in oncology. For investors and the industry, this progress signals a maturing pipeline and a methodical approach to drug development that could lead to a valuable therapeutic asset.
To view the full article, visit https://ibn.fm/whdu9. For more information about Onco-Innovations, visit the company’s website at https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
